BENEFITS AND RISKS OF ADMINISTERING MONOCLONAL ANTIBODY THERAPY FOR CORONAVIRUS (COVID-19)

Course overview

THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), THE CAUSATIVE AGENT IN COVID-19, HAS CREATED A GLOBAL PANDEMIC AND OVERWHELMED HOSPITAL SYSTEMS GLOBALLY. MONOCLONAL ANTIBODY THERAPY HAS BEEN SUGGESTED AS AN OPTION IN PREVENTING PROGRESSION TO SEVERE COVID-19 INFECTION IN HIGH-RISK INDIVIDUALS AND REDUCING HOSPITALIZATIONS. THIS ACTIVITY OUTLINES THE INDICATIONS, ACTIONS, CONTRAINDICATIONS, AND ADVERSE EVENTS FOR MONOCLONAL ANTIBODY THERAPY AS A VALUABLE TREATMENT FOR OUTPATIENT COVID-19 INFECTIONS.